BioXcel Therapeutics to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call and Webcast

Rhea-AI Summary

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) announced a conference call and webcast scheduled for March 11, 2021, at 8:30 AM ET to discuss its fourth quarter and full year 2020 operating and financial results. The company is focused on developing innovative medicines in neuroscience and immuno-oncology through AI techniques. Key projects include BXCL501, targeting agitation and opioid withdrawal, and BXCL701 for aggressive prostate cancer treatment. Further details are available on the company’s website.

Positive

• Host of a conference call to discuss Q4 and full year 2020 results, indicating transparency and engagement with shareholders.
• Focus on innovative AI-driven approaches to drug development, potentially differentiating the company in the biotech sector.

Negative

• No specific financial metrics or results disclosed in the PR, leaving investors with uncertainty before the scheduled call.

NEW HAVEN, Conn., March 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Thursday, March 11, 2021 at 8:30 AM Eastern Time to discuss its fourth quarter and full year 2020 operating and financial results.

Conference Call & Webcast Details
Date/Time: Thursday, March 11, 2021, 8:30 AM Eastern Time
Domestic: 877-407-2985
International: 201-378-4915

The webcast will be accessible* under "Events" on the News & Media page of the Company's website at www.bioxceltherapeutics.com.

Replay
Domestic: 877-660-6853
International: 201-612-7415
Conference ID: 13716684

*Replay available through at least March 25, 2021

BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel’s two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. For more information, please visit www.bioxceltherapeutics.com.

Contact Information:

BioXcel Therapeutics, Inc.
www.bioxceltherapeutics.com

Investor Relations:
Mary Coleman
BioXcel Therapeutics, VP of Investment Relations
MColeman@bioxceltherapeutics.com
1.475.238.6837

John Graziano
Solebury Trout
jgraziano@soleburytrout.com
1.646.378.2942

Media:

Julia Deutsch
Solebury Trout
jdeutsch@soleburytrout.com
1.646.378.2967

FAQ

What date is BioXcel's conference call for Q4 2020 results?

The conference call is scheduled for March 11, 2021, at 8:30 AM Eastern Time.

What is the purpose of BioXcel Therapeutics' upcoming conference call?

The call will discuss the company's fourth quarter and full year 2020 operating and financial results.

Which drugs are BioXcel's main focus in their clinical development?

BioXcel is focused on BXCL501 for agitation and opioid withdrawal, and BXCL701 for aggressive prostate cancer.

How can I access the conference call and webcast for BioXcel Therapeutics?

The webcast can be accessed under 'Events' on BioXcel's News & Media page.

What is the stock symbol for BioXcel Therapeutics?

The stock symbol for BioXcel Therapeutics is BTAI.